# US 2025/0041392 A1 · Compositions and methods for treatment of homocystinuria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0041392 A1
- Document ID: US20250041392A1
- Status: Published application
- Kind: A1
- Application number: 18/658,735
- Filed: 2024-05-08
- Published: 2025-02-06
- Earliest claimed: 2013-01-29
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a Body Corporate
- Inventors: Jan P. Kraus; Tomas Majtan; Erez Bublil
- Web page: https://patentgrep.com/patent/US20250041392A1

## CPC

- A61K 38/51: Lyases (4)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C12N 9/88: Lyases (4.)
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 402/01022: Cystathionine beta-synthase (4.2.1.22)
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

## Claims

### Claim at position 1

1-33. canceled

### Claim 34

An isolated polypeptide dimer comprising two monomeric human truncated cystathionine β-synthase (htCBS) mutant polypeptide subunits, wherein each monomeric htCBS mutant polypeptide subunit independently comprises:
an amino acid sequence sharing an amino acid sequence identity of at least 80%, at least 90%, at least 95%, or at least 99% compared with SEQ ID NO:2, wherein the amino acid sequence of the htCBS mutant polypeptide further comprises
a carboyxyl-terminal truncation, wherein the truncation comprises residues 383-551, 397-551, 414-551, 442-551, 489-551, 497-551, 524-551, 534-551, or 544-551 of SEQ ID NO: 2; and
a mutation of a cysteine to a serine at amino acid position 15 (C15S) compared to a cystathionine B-synthase (CBS) protein comprising the amino acid sequence of SEQ ID NO: 2;
wherein each htCBS mutant polypeptide subunit is independently covalently linked to at least one polyethylene glycol (PEG) molecule, wherein the at least one PEG molecule is an NHS ester-activated PEG molecule or has a molecular weight greater than or equal to 20 kDa.

### Claim 35 (depends on 34)

The isolated polypeptide dimer of claim 34, wherein each monomeric htCBS mutant polypeptide subunit independently comprises an amino acid sequence sharing an amino acid sequence identity of at least 99% compared with SEQ ID NO: 2.

### Claim 36 (depends on 34)

The isolated polypeptide dimer of claim 34, wherein the carboxyl-terminated truncation of each monomeric htCBS mutant polypeptide subunit comprises residues 414-551 of SEQ ID NO: 2.

### Claim 37 (depends on 34)

The isolated polypeptide dimer of claim 34, wherein each monomeric htCBS mutant polypeptide subunit is independently covalently linked to a plurality of PEG molecules, wherein each PEG molecule is an NHS ester-activated PEG molecule having a molecular weight greater than or equal to 20 kDa.

### Claim 38 (depends on 34)

The isolated polypeptide dimer of claim 34, wherein each PEG molecule covalently linked to each htCBS mutant polypeptide subunit is independently an unbranched PEG molecule or a branched PEG molecule.

### Claim 39

An isolated polypeptide dimer comprising two monomeric human truncated cystathionine β-synthase (htCBS) mutant polypeptide subunits, wherein each monomeric htCBS mutant polypeptide subunit independently comprises an amino acid sequence sharing an amino acid sequence identity of at least 99% compared with SEQ ID NO: 13, wherein each htCBS mutant polypeptide subunit is independently covalently linked to at least one 20 kDa NHS ester-actived PEG molecule.

### Claim 40 (depends on 39)

The isolated polypeptide dimer of claim 39, wherein each monomeric htCBS mutant polypeptide subunit independently comprises amino acids 2-413 of the amino acid sequence of SEQ ID NO: 13.

### Claim 41 (depends on 40)

The isolated polypeptide dimer of claim 40, wherein each monomeric htCBS mutant polypeptide subunit is independently covalently linked to a plurality of independent 20 kDa NHS ester-actived PEG molecules.

### Claim 42 (depends on 41)

The isolated polypeptide dimer of claim 41, wherein the polypeptide dimer is purified from other protein components such that the polypeptide dimer comprises at least about 80% weight/weight of the total protein in a given composition, at least about 85% weight/weight of the total protein in a given composition, at least about 90% weight/weight of the total protein in a given composition, at least about 91% weight/weight of the total protein in a given composition, at least about 92% weight/weight of the total protein in a given composition, at least about 93% weight/weight of the total protein in a given composition, at least about 94% weight/weight of the total protein in a given composition, at least about 95% weight/weight of the total protein in a given composition, at least about 96% weight/weight of the total protein in a given composition, at least about 97% weight/weight of the total protein in a given composition, at least about 98% weight/weight of the total protein in a given composition, or at least about 99 weight/weight of the total protein in a given composition.

### Claim 43 (depends on 42)

The isolated polypeptide dimer of claim 42, wherein the isolated polypeptide dimer is non-heme binding and remains catalytically active.

### Claim 44 (depends on 41)

A pharmaceutical composition comprising:
a therapeutically effective amount of the isolated polypeptide dimer of claim 41; and
a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 45 (depends on 41, 44)

A method for treating or ameliorating a disease, disorder, or condition associated with elevated homocysteine in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated polypeptide dimer of claim 41 or a pharmaceutical composition of claim 44.

### Claim 46 (depends on 41, 44)

A method for increasing the amount of a metabolite in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated polypeptide dimer of claim 41 or a pharmaceutical composition of claim 44, wherein the metabolite is cystathionine or cysteine.

### Claim 47 (depends on 41, 44)

A method for decreasing the amount of a metabolite in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated polypeptide dimer of claim 41 or a pharmaceutical composition of claim 44, wherein the metabolite is homocysteine, methionine, or S-adenosyl homocysteine.

### Claim 48 (depends on 41, 44)

A method for treating liver disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated polypeptide dimer of claim 41 or a pharmaceutical composition of claim 44.

### Claim 49 (depends on 41, 44)

A method for treating homocystinuria or homocysteine remethylation disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated polypeptide dimer of claim 41 or a pharmaceutical composition of claim 44.

### Claim 50 (depends on 49)

The method of claim 49, wherein the homocystinuria or homocysteine remethylation disorder is mental retardation, osteoporosis, ectopia lentis, kyphoscoliosis, stroke, myocardial infarction, or pulmonary embolism.

### Claim 51 (depends on 49)

The method of claim 49, wherein the subject in need is also administered one or more of an anti-coagulant, a statin, a relaxed protein restricted diet, anethole dithiolethione, or betaine.

### Claim 52 (depends on 51)

The method of claim 51, wherein betaine is administered twice daily.

### Claim 53 (depends on 51)

The method of claim 51, wherein the individual is on a relaxed protein restricted diet.

### Claim 54 (depends on 49)

The method of claim 49, wherein the isolated polypeptide dimer is administered to the subject in need thereof by an implanted osmotic pump, intravenous administration, subcutaneous administration, or intraperitoneal administration.
